Focus: Vantive is a biotechnology company headquartered in Deerfield, IL, specializing in vital organ therapy products and digital solutions focused on nephrology. The company maintains a portfolio of dialysis solutions and related therapies for renal failure management.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
No open roles listed right now. Follow Vantive to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Hypertonic peritoneal dialysis solution used as primary osmotic agent; cornerstone DIANEAL franchise facing exclusivity cliff.
Help build intelligence for Vantive
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Vantive's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Replacement therapy solution for critical care; part of PRISMASOL family approaching patent cliff.
Higher-concentration peritoneal dialysis formulation; subject to near-term generic entry.
CRRT solution variant approaching exclusivity cliff.
DIANEAL formulation variant with electrolyte optimization; LOE approaching.
Specialized low-calcium DIANEAL formulation for patients with calcium dysregulation; subject to near-term generic competition.
CRRT electrolyte-balanced variant; approaching patent cliff.
B22GK formulation variant; part of declining PRISMASOL franchise.
Lower-concentration B22GK formulation; approaching exclusivity cliff.
Higher-concentration B22GK variant; part of franchise facing near-term generic competition.
17 discontinued, 19 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo